Vinflunine: Drug safety evaluation of this novel synthetic vinca alkaloid

Expert Opinion on Drug Safety

Volumn 10, Issue 4, 2011, Pages 645-653

  Schutz, Fabio A B ^a   Bellmunt, Joaquim ^b   Rosenberg, Jonathan E ^a   Choueiri, Toni K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

antitubulin; bladder cancer; javlor; microtubule inhibitor; safety; transitional cell cancer; urothelial cancer; vinca alkaloid; vinflunine

Indexed keywords

CISPLATIN; DOCETAXEL; TRASTUZUMAB; VINFLUNINE;

ABDOMINAL PAIN; ADVANCED CANCER; ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL STUDY; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DYSPNEA; EDEMA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HEART FAILURE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); SEPTIC SHOCK; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; NEOPLASMS; VINBLASTINE; VINCA ALKALOIDS;

EID: 79958799803     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.581660     Document Type: Article

References (37)

1. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001;40(2):159-73 (Pubitemid 33001600)
2. Jacquesy JC, Fahy J. Cancer: superacidic generation of new antitumor agents; applying chemical principles to the understanding and treatment of disease. In: Torrence PF, editor, Biomedical Chemistry. Wiley-Interscience, New York; 2000. p. 227-46
3. Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 1999;10(3):512-20 (Pubitemid 29151954)
4. Kruczynski A, Barret JM, Etievant C, et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 1998;55(5):635-48 (Pubitemid 28077822)
5. Kruczynski A, Colpaert F, Tarayre JP, et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 1998;41(6):437-47 (Pubitemid 28140706)
6. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2(1):1-17 (Pubitemid 34649866)
7. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003;2(5):427-36
8. Ngan VK, Bellman K, Panda D, et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000;60(18):5045-51
9. Ngan VK, Bellman K, Hill BT, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001;60(1):225-32 (Pubitemid 32595250)
10. Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 2003;14(4):630-7 (Pubitemid 41295094)
11. Zhao XP, Zhong J, Liu XQ, Wang GJ. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. Acta Pharmacol Sin 2007;28(1):118-24 (Pubitemid 46046635)
12. Johnson P, Geldart T, Fumoleau P, et al. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs 2006;24(3):223-31 (Pubitemid 43738961)
13. Vermorken JB, Stupp R, Nguyen L, et al. Phase I Study of IV vinflunine given on a weekly schedule in previously untreated patients (pts) with advanced solid tumors. J Clin Oncol 2003;22(18S):abstract 887
14. Lekas A, Papathomas TG, Papatsoris AG, et al. Novel therapeutics in metastatic bladder cancer. Expert Opin Investig Drugs 2008;17(12):1889-99
15. Gerullis H, Ecke T, Eimer C, et al. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review. Anticancer Drugs 2011;22(1):9-17
16. Mamtani R, Vaughn DJ. Vinflunine in the treatment of advanced bladder cancer. Expert Rev Anticancer Ther 2011;11(1):13-20
17. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94(10):1395-401 (Pubitemid 43772272)
18. Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009;115(18):4110-17
19. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454-61
20. Culine S, Lucas S, Salhi Y, Bellmunt J. Updated survival results of the phase III trial comparing vinflunine (V) to best supportive care (BSC) in advanced transitional cell cancer of the urothelium (TCCU) after failure of a prior platinum-containing regimen. Eur Urol Suppl 2010;9:38
21. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28(11):1850-5
22. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008;3(4):430-40 (Pubitemid 351489488)
23. Krzakowski M, Ramlau R, Jassem J, et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 2010;28(13):2167-73
24. Souquet PJ, Krzakowski M, Ramlau R, et al. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2010;11(2):105-13
25. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 2006;95(9):1161-6 (Pubitemid 44658478)
26. Fumoleau P, Cortes-Funes H, Taleb AB, et al. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/ taxane-based chemotherapy. Am J Clin Oncol 29 May 2009. [Epub ahead of print]. Available online from: http://www.ncbi.nlm.nih. gov/ pubmed/19487917
27. Yardley DA, McCleod M, Schreiber F, et al. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest 2010;28(9):925-31
28. Paridaens R, Wildiers H, Dalenc F, et al. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. J Clin Oncol 2007;25(18S):abstract 1058
29. Paule B, Saliba F, Gil-Delgado M, et al. Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): pharmacokinetic results. J Clin Oncol 2007;25(18S):abstract 2523
30. Spigel DR, Hainsworth JD, Lane CM, et al. Phase II trial of vinflunine in relapsed small cell lung cancer. J Thorac Oncol 2010;5(6):874-8
31. Hainsworth JD, Meluch AA, Lane CM, et al. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium. Cancer Invest 2010;28(3):275-9
32. Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007;25(30):4751-6 (Pubitemid 350086477)
33. Olver IN, Byrne MJ, Walpole E, et al. Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma. Eur J Cancer 2007;43(12):1829-32 (Pubitemid 47243653)
34. Bennouna J, Breton JL, Tourani JM, et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 2006;94(10):1383-8 (Pubitemid 43772270)
35. Goldstein D, Ackland SP, Bell DR, et al. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest New Drugs 2006;24(5):429-34 (Pubitemid 43876079)
36. Stinchcombe TE, Lee CB, Hayes DN, et al. Preliminary safety and efficacy data of a phase II trial of vinflunine and cetuximab in the second-line treatment of patients with advanced non-small cell lung cancer. J Clin Oncol 2008;26(20 Suppl):abstract 19100
37. Kaleta R, Chung HC, Park SR, et al. Single agent IV vinflunine (VFL) in the second-line treatment of patients (pts) with advanced gastric cancer (AGC): initial results of a phase II trial. J Clin Oncol 2008;26(20 Suppl):abstract 15533